MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its lead Alzheimer’s candidate. The study compared the new dihydrate crystal to the original anhydrous form across animal and human trials.
The findings confirmed that the crystal form preserves the absorption, metabolism, and clearance properties of the original compound, ensuring consistency in therapeutic efficacy while offering greater stability. The new dihydrate structure incorporates two moles of water, improving durability without altering performance.
“We have highlighted the new form of buntanetap in prior presentations, but this open-access publication presents the data in full to a broader audience,” said Alexander Morin, Ph.D., Director of Strategic Communications at Annovis. “It validates the use of crystal buntanetap in clinical trials and reinforces the consistency and reliability of our lead asset.”
The crystal form is now being used in Annovis’ pivotal Phase 3 Alzheimer’s trial (NCT06709014), which is enrolling patients across the United States. The study is expected to produce a symptomatic readout in fall 2026 and a disease-modifying readout in fall 2027.
In addition to supporting the ongoing clinical program, the new form extends intellectual property protection for buntanetap into the 2040s, covering its mechanism of action, therapeutic uses, and potential combination therapies.
The full article is available through the Publications library on Annovis’ website.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.